Inovio to Start a Phase 1/2 Study of its COVID-19 Vaccine in South Korea

Inovio (NASDAQ: INO) is partnering with the International Vaccine Institute and Seoul National University Hospital to run a phase 1/2 clinical trial of Inovio's COVID-19 vaccine INO-4800 in South Korea. The study is being funded through a $6.9 million grant from the Coalition for Epidemic Preparedness Innovations. The Korea Center for Disease Control and Prevention/Korea National Institute of Health is also supporting the clinical trial.